Delving into the Latest Updates on Anti-FcRH5/CD3 T-cell dependent bispecific antibody (Genentech) with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms-

Target

CD3 x EPO receptor

Action

inhibitors, antagonists

Mechanism

CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), EPO receptor antagonists(Erythropoietin receptor antagonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Multiple Myeloma

Originator Organization

Genentech, Inc.

Active Organization-

Inactive Organization

Genentech, Inc.

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Author: Hötzel, Isidro ; Hristopoulos, Maria ; Sukumaran, Siddharth ; DiCara, Danielle ; Clark, Vanessa ; Ellerman, Diego ; Harris, Michael J ; Totpal, Klara ; Wu, Thomas D ; Lee, Genee Y ; Ye, Zhengmao ; Menzies, Sam A ; Danilenko, Dimitry ; Johnston, Jennifer ; Cook, Ryan ; Stagg, Nicola J ; Li, Ji ; Junttila, Teemu T ; Nakamura, Rin ; Luis, Elizabeth ; McCarty, Luke ; Sumiyoshi, Teiko ; James, John R ; Slaga, Dionysos

The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation by inducing target clustering and exclusion of CD45 phosphatase from the synapse. The dimensions of the target molecule play a key role in the efficiency of the synapse formation. The anti-FcRH5/CD3 TDB kills human plasma cells and patient-derived myeloma cells at picomolar concentrations and results in complete depletion of B cells and bone marrow plasma cells in cynomolgus monkeys. These data demonstrate the potential for the anti-FcRH5/CD3 TDB, alone or in combination with inhibition of PD-1/PD-L1 signaling, in the treatment of MM and other B cell malignancies.

100 Deals associated with Anti-FcRH5/CD3 T-cell dependent bispecific antibody (Genentech)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Preclinical	United States	Genentech, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data